Please wait while we load the requested 10-K report or click the link below:
EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress
- Total revenues of $8.6 million in Q4 2019 and $20.4 million for full year 2019 -
- Net product revenues of $7.9 million in Q4 2019 and $16.8 million for full year 2019 -
- Q4 2019 customer demand for DEXYCU and YUTIQ Increased 111% and 59%, respectively, compared to Q3 2019 -
- EYP-1901, a six-month sustained release anti-VEGF potential treatment for wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion advancing toward clinical development -
– Management to host a conference call and webcast today at 8:30 AM ET -
WATERTOWN, Mass., March 5, 2020 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported financial results for the fourth quarter and full year ended December 31, 2019 and highlighted recent corporate developments.
“Q4 2019 was a pivotal quarter for EyePoint as we continued our commercial momentum, serving an increasing number of patients who suffer from ocular diseases and need better treatment options,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “Our commercial launch initiatives for DEXYCU® and YUTIQ® are driving increased reception and adoption from the ophthalmology community resulting in strong customer demand and sales growth in the fourth quarter for both products. We anticipate that these initiatives coupled with additional access agreements with ambulatory surgery centers and integrated healthcare networks, continued target account penetration and education efforts with key opinion leaders will continue to drive customer demand throughout 2020.”
Ms. Lurker continued, “We are very excited about our lead development asset EYP-1901, an anti-VEGF, tyrosine kinase inhibitor (TKI) six-month sustained release potential therapy using our bioerodible Durasert® technology targeting wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. These indications represent large markets with patient populations in need of treatments that require fewer injections and more consistent drug delivery to control their serious eye diseases.”
Commercial Performance in Fourth Quarter 2019
DEXYCU (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery
The following information was filed by Eyepoint Pharmaceuticals, Inc. (EYPT) on Thursday, March 5, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Eyepoint Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Eyepoint Pharmaceuticals, Inc..